You have free access to this content

HIV Medicine

Cover image for Vol. 11 Issue 5

May 2010

Volume 11, Issue 5

Pages 289–352

  1. Original research

    1. Top of page
    2. Original research
    3. Short communications
    1. You have free access to this content
      Hospitalization risk following initiation of highly active antiretroviral therapy (pages 289–298)

      SA Berry, YC Manabe, RD Moore and KA Gebo

      Version of Record online: 8 DEC 2009 | DOI: 10.1111/j.1468-1293.2009.00776.x

    2. You have free access to this content
      Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme (pages 299–307)

      DM Moore, W Zhang, B Yip, M Genebat, VD Lima, JSG Montaner and RS Hogg

      Version of Record online: 8 DEC 2009 | DOI: 10.1111/j.1468-1293.2009.00779.x

    3. You have free access to this content
      Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France (pages 308–317)

      EK Déti, R Thiébaut, F Bonnet, S Lawson-Ayayi, M Dupon, D Neau, JL Pellegrin, D Malvy, S Tchamgoué, F Dabis, P Morlat and for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)

      Version of Record online: 9 DEC 2009 | DOI: 10.1111/j.1468-1293.2009.00780.x

    4. You have free access to this content
    5. You have free access to this content
      Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection (pages 326–333)

      M Fabbiani, S Di Giambenedetto, E Ragazzoni, M Colafigli, M Prosperi, R Cauda, P Navarra and A De Luca

      Version of Record online: 11 JAN 2010 | DOI: 10.1111/j.1468-1293.2009.00785.x

    6. You have free access to this content
      Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts (pages 334–344)

      P Munderi, AS Walker, C Kityo, AG Babiker, F Ssali, A Reid, JH Darbyshire, H Grosskurth, P Mugyenyi, DM Gibb, CF Gilks and on behalf of the DART/NORA trial teams

      Version of Record online: 2 FEB 2010 | DOI: 10.1111/j.1468-1293.2009.00786.x

  2. Short communications

    1. Top of page
    2. Original research
    3. Short communications
    1. You have free access to this content
      Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients (pages 345–348)

      M Parczewski, M Leszczyszyn-Pynka, A Wnuk, A Urbañska, K Fuksiñska, D Bander and A Boroñ-Kaczmarska

      Version of Record online: 11 JAN 2010 | DOI: 10.1111/j.1468-1293.2009.00787.x

    2. You have free access to this content
      Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2 (pages 349–352)

      S Ghezzi, F Pacciarini, S Nozza, S Racca, SA Mariani, E Vicenzi, A Lazzarin, F Veglia, G Tambussi and G Poli

      Version of Record online: 8 DEC 2009 | DOI: 10.1111/j.1468-1293.2009.00782.x

SEARCH

SEARCH BY CITATION